KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Neogenomics (NEO) over the last 17 years, with Q3 2025 value amounting to 0.09%.

  • Neogenomics' Return on Capital Employed fell 300.0% to 0.09% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.09%, marking a year-over-year decrease of 300.0%. This contributed to the annual value of 0.07% for FY2024, which is 0.0% changed from last year.
  • Per Neogenomics' latest filing, its Return on Capital Employed stood at 0.09% for Q3 2025, which was down 300.0% from 0.08% recorded in Q2 2025.
  • Over the past 5 years, Neogenomics' Return on Capital Employed peaked at 0.02% during Q2 2021, and registered a low of 0.1% during Q3 2022.
  • For the 5-year period, Neogenomics' Return on Capital Employed averaged around 0.07%, with its median value being 0.07% (2024).
  • As far as peak fluctuations go, Neogenomics' Return on Capital Employed crashed by -800bps in 2022, and later skyrocketed by 300bps in 2023.
  • Quarter analysis of 5 years shows Neogenomics' Return on Capital Employed stood at 0.07% in 2021, then crashed by -44bps to 0.1% in 2022, then increased by 28bps to 0.07% in 2023, then fell by -1bps to 0.07% in 2024, then crashed by -37bps to 0.09% in 2025.
  • Its Return on Capital Employed stands at 0.09% for Q3 2025, versus 0.08% for Q2 2025 and 0.07% for Q1 2025.